All In Biotech

Drug Trial Radar · NCT06817239

Effect of Low-dose EsketaMine on dElirium in High-risk Elderly Patients uNdergoing elecTive Surgery (ELEMENT)

Effect of Perioperative Low-dose EsketaMine on dElirium in High-risk Elderly Patients uNdergoing elecTive Major Non-cardiac Surgery: a Multi-center Randomized Trial (ELEMENT Trial)

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,670 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,670

Planned (sponsor's estimate)

Start

Feb 12, 2025

Primary completion

Jun 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 65 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Delirium is an acutely occurred neurocognitive disorder characterized by fluctuating symptoms of inattention, altered consciousness and cognitive dysfunction. Delirium is reported to occur in 4% to 65% of postoperative patients depending on the population, and is especially common in older patients. Postoperative delirium is disturbing to patients and their families, and it is a strong predictor of both early and long-term worse outcomes including increased non-delirium complications, increased perioperative mortality, shortened overall survival, declined cognitive function, and lowered quality of life. Although ketamine/esketamine has anti-inflammatory and neuroprotective effects, evidence on its efficacy in reducing postoperative delirium remains inconsistent and inconclusive. Existing studies are limited by heterogeneity, small sample sizes, single-center designs, and a focus on specific type of surgery. Research on elderly high-risk patients is lacking, and most studies administer the drug intraoperatively, with limited exploration of postoperative use. The optimal dosing and timing for POD prevention are unclear. This study aims to carry out a multicenter, single-blind, placebo-controlled, large-sample randomized controlled trial assessing the effect of low-dose esketamine, given intraoperatively and postoperatively, on delirium in elderly high-risk patients undergoing major non-cardiac surgery.

Conditions

  • Delirium in Old Age
  • Delirium, Postoperative
  • Anesthesia
  • Cognitive Dysfunction
  • Pain, Postoperative
  • Esketamine
  • Non-cardiac Surgery

Interventions

  • EsketamineDrug

    Esketamine (1mg/ml) will be administered at a loading dose of 0.2 mg/kg, namely at a infusion rate of 1.2ml/kg/h over 10 minutes after induction, then a maintenance infusion rate of 0.1 mg/kg/h until 40 minutes before the end of the surgery. For postoperative analgesia, patient-controlled intravenous analgesia (PCIA) is prepared with a formulation consisting of esketamine 50mg and sufentanil 200 μg, diluted to a total volume of 200 ml. The background dose is set at 2 ml/h, with a bolus dose of 2 ml and a lockout interval of 15 minutes.

  • Normal salineDrug

    Normal saline will be administered at a infusion rate of 1.2ml/kg/h over 10 minutes after induction, then a maintenance infusion rate of 0.1 mg/kg/h until 40 minutes before the end of the surgery. For postoperative analgesia, patient-controlled intravenous analgesia (PCIA) is prepared with sufentanil 200μg, diluted to a total volume of 200 ml. The background dose is set at 2 ml/h, with a bolus dose of 2 ml and a lockout interval of 15 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of delirium within 5 days after surgeryTime frame: Up to 5 days after surgery
  2. Quality of recovery on postoperative day 1 (Sub-study)Time frame: On postoperative day 1

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of JiNan University

    Guangzhou, Guangdong, China · Active not recruiting

  • The Eighth Affliated Hospital of Southern Medical Universily

    Guangzhou, Guangdong, China · Recruiting

  • Ganzhou People's Hospital

    Ganzhou, Jiangxi, China · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.